LSL Pharma Group announces its fiscal Q3-24 results
Summary
LSL Laboratory completed the installation of additional production equipment during the quarter to take full advantage of the capacity created by the plant relocation in 2023. Net loss in FY-24 has decreased over prior year period as the Corporation delivered stronger operating performance while controlling its financial expenses and limiting share-based compensation costs. Our Adjusted EBITDA results to date in 2024 demonstrate the improvement of our financial performance as we continue to take advantage of our increased operating capacity while controlling our expenses. None On November 6, 2024, the Corporation announced having secured $1.4 million on new orders from international clients, as well as having completed the initial phase of production scale up at its Steri-Med Pharma plant. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing, and commercialization of high-quality sterile ophthalmic pharmaceuticals, as well as natural health products in solid and liquid dosage forms.